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ABSTRACT 
According to WHO, Adverse drug reaction (ADR) is defined as “any response to a drug which is noxious and unintended, and which occurs at 
doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function”. Adverse drug 
reactions occur almost daily in every health care institution and can adversely affect a patient’s quality of life (QOL), often causing considerable 
morbidity and mortality. With the setting up of the Pharmacovigilance Program in India, it is important for all psychiatrists, pharmacist and 
nurses to familiarize themselves with the key principles of this science, and to apply the principle of Pharmacovigilance for the welfare of our 
patients and the entire health care community. 
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According to WHO, Adverse drug reaction(ADR) is defined as 
“any  response to a drug which is noxious and unintended, 
and which occurs at doses normally used in man for the 
prophylaxis, diagnosis, or therapy of disease, or for the 
modifications of physiological function”.An adverse drug 
reaction (ADR) is an unwanted, undesirable effect of a 
medication that occurs during usual clinical use.1 Adverse 
drug reactions occur almost daily in every health care 
institutions and can adversely affect a patient’s quality of life 
(QOL), often causing considerable morbidity and mortality. 
Serious attention has been given to identifying the patient 
populations most at risk, the drugs most commonly 
responsible, and the potential causes of ADRs. It is mainly 
due to an an increase in the number of drugs on the market, 
an aging population, and a trend of poly-pharmacy. Adverse 
drug reactions may cause patients to lose their confidence 
,negative emotions toward their healthcare profession & 
institution and seek self-medication practice, which may 
results in additional ADRs.2 With 10% of 3.63 trillion 
medicines popped worldwide in 2015, India is the world’s 
third-largest medicine market. It stands to scientific reason 
that these drugs will have side effects. Yet, in 2013, India 
reported no more than 2% of globally occurring adverse 
drug reactions; jargon for side effects of medicines, logged in 
a database maintained by the Uppsala Monitoring Centre .It 
isn’t as if drugs have fewer side effects in India. Serious 
effects were seen in 6.7% of patients, a 2014 study reported. 
Other studies have cited drug side effects as the reason for 
3.4% of hospital admissions in India, 3.7% hospital 
re-admissions, and 1.8% mortality. In the developed world, 
adverse reactions are believed to be the fourth-leading cause 
of death. Within India, the adverse drug reaction reporting 
rate (ADRs reported per million population) has almost 
doubled in the last three years to 40, but it is lower than 130, 
the average ADR reporting rate for high-income countries, 
and clearly disproportionate to the country’s population and 
medicine consumption.3  
Pharmacovigilance (PV) is defined as the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any 
other drug-related problem. WHO established its 
Programme for International Drug Monitoring in response to 
the thalidomide disaster detected in 1961. Together with the 
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WHO Collaborating Centre for International Drug Monitoring, 
Uppsala, WHO promotes PV at the country level. At the end 
of 2010, 134 countries were part of the WHO PV Programme. 
The aims of PV are to enhance patient care and patient safety 
in relation to the use of medicines; and to support public 
health programmes by providing reliable, balanced 
information for the effective assessment of the risk-benefit 
profile of medicines.4 
Evolution of Pharmacovigilance  
The birth of Pharmacovigilance has a close relationship to 
psychiatry.Thalidomide was first synthesized in 1953 and 
became popular as a sedative prescribed for the morning 
sickness associated with pregnancy. By 1958, thalidomide 
was being advertised and promoted around the world. In 
April 1961, obstetrician William McBride began to notice 
cases of a rare birth defect, Phocomelia in babies whose 
mothers had used thalidomide in pregnancy. At the Crown St. 
Women’s Hospital in Sydney, Australia, where McBride 
practiced, he soon persuaded the hospital to stop using the 
drug and wrote of his concerns to Distillers, the company 
that sold the drug in Australia. At about the same time, 
pediatrician and geneticist Widukind Lenz noted many 
similar cases in Germany, where thalidomide was available 
without prescription. At this time, physicians assumed that 
the placenta was impervious to any drugs the expectant 
mother ingested—unless the drug actually killed her. This 
belief persisted despite experimental evidence to the 
contrary. Since thalidomide was not fatal in overdose, it was 
deemed safe. When thalidomide was approved, drugs were 
not tested in pregnant animals for their teratogenic 
effect—that is, for their ability to cause developmental 
abnormalities in the fetus. McBride wrote the letter below to 
a leading medical journal, The Lancet, to alert the medical 
community to the dangers of thalidomide, from that moment 
the era of Pharmacovigilance was started. 5, 6-13 
Chronological Development of Pharmacovigilance 
1747: James Ling reported clinical trial showing 
effectiveness of lemon juice in prevention of scurvy. 
1937: Sulphanilamide disaster, where sulphonamide was 
dissolved in diethyleneglycol leading to death of more than 
100 people because of renal failure. 
1938: The preclinical toxicity and pre-marketing clinical 
studies made mandatory by FDA. 
1950s: Aplastic anaemia caused due to use of 
chloramphenicol. 
1960: The FDA started hospital based drug monitoring 
program. 
1961: Thalidomide disaster. 
1963: 16th world health assembly recognized importance to 
rapid action on ADR. 
1968: Establishment of International Drug Monitoring 
Program by WHO. 
1970s: Clioquinol was found to be linked with 
Sub-acute-myelo-optic neuropathy. 
1980s and 1990s: Many drugs with serious adverse effects 
were recorded. 
1996: India started global standard clinical trial. 
1997: India joined ADR Monitoring Program. 
1998: PV activity initiated in India. 
2002: 67th National Pharmacovigilance Centre established in 
India. 
2005: India started conducting structured clinical trials. 
2009-2010: PV plan of India was initiated and implemented. 
15th April 2011: The NCC was transferred from AIIMS, New 
Delhi to IPC, and Ghaziabad for smooth and efficient 
functioning of program. 
Till January 2017:  250 AMCs (government and non- 
government) have been established under PvPI.7 
The discipline of Pharmacovigilance is of particular 
importance in the field of psychiatry. Pharmacotherapy is the 
principal modality of management in several psychiatric 
disorders and psychotropic drugs are associated with a 
variety of adverse drug reactions. Over the past decades, 
Pharmacovigilance activity has led to the identification of 
several adverse drug reactions caused by psychotropic drugs, 
resulting in their withdrawal from the market or restrictions 
in use. Psychotropic medications are often administered for 
longer periods and are commonly prescribed in combination 
with other drugs and, therefore, may be involved in clinically 
relevant drug interactions. Psychotropic agents may be 
prescribed to populations at higher risk of developing 
adverse effects. In particular, they are increasingly used to 
treat psychiatric disorders in children and adolescents, as 
well as in the elderly, and may be used by pregnant or 
lactating women. The main source of knowledge on 
tolerability and safety of psychotropic drugs comes from 
clinical trials, but this is associated with several limitations. 
Pharmacovigilance programs are designed to gather 
information on what effects drugs have in the real world 
rather than in groups of carefully selected clinical trial 
populations. For the above mentioned reasons, it is 
important that psychiatrists become familiar with the 
concepts and methods of pharmacovigilance as they have a 
key role in identifying and reporting new or serious adverse 
drug effects.4  
Four reasons why this field is of special 
importance to psychiatrists. 
First, often, patients do not respond to initial drug therapy, 
and may require several trials of different medications. Some 
patients may require a combination of various drugs which 
can increase the risk of adverse effects or drug interactions. 
Second, most clinical trials of psychotropics are conducted 
in “ideal” conditions patients are selected according to 
stringent criteria, and comorbid medical conditions are 
usually excluded. These trials also tend to be short-term, 
lasting for a few weeks or months. In this context, ADRs that 
were not noticed in the context of a trial become more 
apparent, and the burden of managing them falls on the 
psychiatrist. 
Third, there is a publication bias in clinical trials, 
particularly those in psychiatry. Even in published trials, 
ADRs are not always reliably reported, and there is a concern 
that relevant data may be misrepresented in some cases.11 
Hence, the onus is on treating psychiatrists to identify such 
reactions and report them, particularly those related to 
newer drugs. 
Fourth, psychotropics directly affect brain functioning, and 
can produce undesirable changes in behavior. Sometimes, 
these changes can be life-threatening, as in the case of 
suicidal behavior induced by antidepressants in children. 12 
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The benefits of pharmacovigilance in a psychiatric 
setting 
The positive effects of pharmacovigilance in psychiatry can 
be broadly divided into four categories: Benefits to the 
patient, benefits to clinicians, benefits to the pharmaceutical 
industry, and benefits to regulatory authorities. 
1. Benefits to the patient: Most adverse drug events, even if 
not life-threatening, can be distressing and troublesome to 
patients. Reporting these events could help in building trust 
between patients and physicians.  The practice of regular 
reporting can also lead to earlier identification of problems, 
which can improve patient compliance and quality of life. 
2. Benefits to the physician: The practice of 
pharmacovigilance can help psychiatrists to identify and 
manage potential ADRs. In several cases, physicians may be 
responsible for bringing a particular ADR to light, and can 
gain credit for this. This is particularly the case for events 
such as behavioral toxicity (drug-induced mania, 
drug-induced suicidality) that are best recognized by 
practitioners who are in close contact with their patients. 
3. Benefits to the pharmaceutical industry: The role of the 
pharmaceutical industry in psychiatry has come under fire 
recently, with reports of serious ADRs being under-reported 
and suppressed during trials. If the principal investigators in 
such trials develop a “culture of pharmacovigilance,” then 
such ADRs can be identified at the earliest possible stage, 
and necessary action taken before the drug is marketed. The 
CDSCO has made the reporting of adverse reactions by the 
pharmaceutical industry mandatory. This is known as 
“periodic safety update reporting” (PSUR).14 
4. Benefits to regulatory authorities: As mentioned above, 
most published trials of psychotropic medication are 
short-term trials. Regulatory authorities may grant approval 
on the basis of this data, but long-term adverse effects may 
emerge much later. Early “signal detection” of such events 
could help authorities in withdrawing the drug responsible, 
or limiting its use.9
 
Reporting of adverse drug reaction 
What to report?  Life-threatening event or death 
 Hospitalization of the patient 
 Congenital anomaly 
 Medically significant event (If the event is considered serious by physician) 
 Lack of efficacy connected with the use of a medical device or drug product. 
 All suspected drug interactions 
All known or unknown, serious, non-serious, frequent or rare reaction caused due to use of vaccine or 
drug must be reported. 
When to report?  All spontaneous case should be reported within 10 days. 
 All suspected ADR should be reported as soon as possible because over reporting is always better than 
under reporting. 
 Death event must be reported as soon as possible, while all other serious ADR/event needs to report 
within 7 days only. 
 All non-serious cases must be reported within  30 days 
Who can report? Professionals working in healthcare team are the preferred source of information in PV, for example 




 Along with HCPs patient, patient’s relatives, witness or any common person after medical confirmation 
can report. 
How to report? 
 
 Duly filled ADR reporting form needs to send to the nearest AMC or directly to the NCC. 
 Dial toll free helpline number-1800 180 3024 to report ADRs. 
 Mailing the filled ADR reporting form directly to pvpi@ipcindia.net or pvpi.ipcindia@gmail.com. 
 Logging on to the http://www.ipc.gov.in, http://www.ipc.gov.in/PvPI/pv_home.html for list of 
authorized AMCs of India 
Where to report? 
 
Various Peripheral, Regional and Zonal centres have been proposed and established in India . 
 Peripheral PV centre: It is a primary ADR information gathering centre. It includes small medical 
centres, private hospitals, dispensaries, nursing home and pharmacies. ADRs are recognized and 
synchronized by RPCs or ZPCs. Every state, Union territory and few leading medical colleges in India 
have this peripheral centre. 
 Regional PV centre: It’s regarded as secondary PV Centre. It is located in medical college having 
relatively larger facilities. They are identified and coordinated by zonal centres. There are five such 
regional centres in India. 
 Zonal PV centres: It’s regarded as Tertiary PV Centre. Generally located in metro city’s medical college 
having attachment of sufficient facility. It is identified by CDSCO and act as first ADR data collection 
centre. Zonal centre for North and East zone is AIIMS. 
 
Conclusion 
Pharmacovigilance is an essential activity for all health care 
proffesional. In the field of psychiatry, where long-term drug 
therapy is the norm, clinicians are ideally placed to identify 
and report ADRs to regulatory authorities. With the setting 
up of the Pharmacovigilance Program in India, it is important 
for all psychiatrists, pharmacist and nurses to familiarize 
themselves with the key principles of this science, and to 
apply the principle of pharmacovigilance for the welfare of 
our patients and the entire health care community.
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